RecruitingPhase 3NCT05568719
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Studying Hemophilia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- Testing of hepatic AAV Vector integration(diagnostic_test)
- Enrollment
- 173 enrolled
- Eligibility
- 18 years · MALE
- Timeline
- 2022 – 2040
Study locations (16)
- The Regents of the University of California||UC Davis Health, Rancho Cordova, California, United States
- UC Davis Health, Sacramento, California, United States
- UC Davis Ambulatory Care Clinic, Sacramento, California, United States
- UC Davis Hemophilia Treatment Center, Sacramento, California, United States
- UC Davis Medical Center, Sacramento, California, United States
- UCSF Outpatient Hematology Clinic, San Francisco, California, United States
- USF Health Morsani Center For Advanced Healthcare, Tampa, Florida, United States
- The University of South Florida Board of Trustees, Tampa, Florida, United States
- Mississippi Center For Advanced Medicine, Madison, Mississippi, United States
- Cornell University||Joan & Sanford I. Weill Medical College, New York, New York, United States
- Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States
- The Childrens Hospital of Philadelphia Division of Hematology, Philadelphia, Pennsylvania, United States
- Washington Institute for Coagulation, Seattle, Washington, United States
- Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
- Sydney Local Health District (RPAH Zone), Camperdown, New South Wales, Australia
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05568719 on ClinicalTrials.govOther trials for Hemophilia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT07406139PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE3NCT04563520SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisEmory University
- RECRUITINGNCT07101926Monitoring of Anti-TFPI in HemophiliaHospices Civils de Lyon
- RECRUITINGPHASE4NCT06941870Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophySanofi
- RECRUITINGNCT07314983Long-term Anticoagulation in a Patient With Severe Hemophilia AUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE4NCT06940830Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaSwedish Orphan Biovitrum
- RECRUITINGPHASE1NCT06703606A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.Pfizer
- RECRUITINGPHASE3NCT06833983To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia AGritgen Therapeutics Co., Ltd.